Inicure lead compound characterised as a specific agonist for FPR1, which displays a biased signalling profile that leads to a functional selective activating of the human neutrophils class (https://doi.org/10.1002/JLB.2HI0520-317R).
Functional selective FPR1 signaling in favor of an activationof the neutrophil superoxide generating NOX2 complex
EIC Summit and Booster grant awardees
During the EIC Summit 2026, for innovation and interaction with EIC, entrepreneurs and innovations – CEO Peter Olofsson-Sahl,
Researcher – Felix Sanchez Klose
Inicure is growing! We are happy to announce the recruitment of Felix Sanchez Klose to our research department.
AMR Conference Basel – 2026
Inicure particppated in the AMR conference i Basel meeting research collaborators, service providers and potential future commercial partners